Novanta Inc. has announced that its Chief Financial Officer, Robert Buckley, and Chief Operating Officer, Chuck Ravetto, are scheduled to present at the CJS Securities 26th Annual New Ideas Summer Conference. The presentation is set to take place on Thursday, July 9, 2026, in White Plains, NY.

About Novanta

Novanta is a global supplier of core technology solutions for medical, life science, and advanced industrial original equipment manufacturers. The company combines expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery to solve complex technical challenges.

Novanta’s common shares are quoted on Nasdaq under the ticker symbol "NOVT." The company focuses on delivering proprietary technology solutions that offer extreme precision and performance for demanding applications.

Conference Details

For additional information, interested parties can contact Novanta Inc. Investor Relations at (781) 266-5137 or via email at InvestorRelations@novanta.com .

Novanta Inc. has priced a private placement of 2,142,857 common shares at $140.00 per share to institutional and other accredited investors, resulting in expected gross proceeds of approximately $300 million before placement agent fees and offering expenses. The transaction is expected to close on or about June 11, 2026, subject to customary closing conditions. The capital raised will finance the company's definitive agreement to acquire Riverpoint Medical, a category leader in minimally invasive surgical consumables, from Arlington Capital Partners for an upfront cash consideration of $1.2 billion. This acquisition is a strategic move for Novanta to double its recurring medical consumables revenue to approximately $300 million and increase its medical end-market concentration to 60% of total revenue.

Acquisition Financials and Synergies

The total transaction value includes a milestone payment of $250 million scheduled for the first quarter of 2027. The upfront purchase price represents approximately 19x Riverpoint's estimated 2026 Adjusted EBITDA excluding synergies, or approximately 17x including the full value of expected year-5 pro forma synergies. Novanta has identified more than $80 million in potential cumulative profit and cash flow synergies over five years post-closing. Riverpoint Medical is growing its revenue and cash flows at twice the rate of Novanta, with an expected long-term annual revenue growth outlook of 12% to 15%.

Transaction Metrics

Financial Impact and Guidance

The acquisition is immediately accretive to Novanta's Adjusted Diluted Earnings Per Share in 2026. In 2027, the deal is projected to be accretive to revenue growth rate, Adjusted Gross and EBITDA Margins, Adjusted Diluted EPS, and Operating Cash Flows. Novanta expects its net leverage ratio to be approximately 2.7x after closing, with a target to reduce this ratio below 2.3x by year-end 2027. The company confirmed its previously issued Second Quarter and Full Year 2026 financial guidance for the standalone company and plans to update guidance for the combined entity post-closing.

Corporate Profiles

Riverpoint Medical designs and manufactures IP-protected, private-label products for leading medical OEM customers, including suture anchors, implantable materials, and surgical instruments. The company serves sports medicine and cardiovascular surgery applications and is headquartered in Portland, Oregon. Novanta is a global supplier of core technology solutions for medical, life science, and advanced industrial OEMs, with its common shares quoted on Nasdaq under the ticker symbol "NOVT".